KCNN4 and Alzheimer disease: Therefore, it is promising to either directly reposition existing KCa3.1 blockers for AD preclinical proof-of-concept studies and subsequent clinical trials and/or make efforts to optimize existing or newly-discovered compounds for oral availability and brain penetration in order to expedite drug development for AD.